<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022737</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01862</org_study_id>
    <secondary_id>NCI-2012-01862</secondary_id>
    <secondary_id>CDR0000068859</secondary_id>
    <secondary_id>COG-AALL0031</secondary_id>
    <secondary_id>AALL0031</secondary_id>
    <secondary_id>AALL0031</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00022737</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well combination chemotherapy with or without donor&#xD;
      peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia.&#xD;
      Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the&#xD;
      growth of cancer cells. It also helps stop the patient's immune system from rejecting the&#xD;
      donor's stem cells. When the healthy stem cells from a donor are infused into the patient&#xD;
      they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,&#xD;
      and platelets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility of treatment with intensified chemotherapy, in terms of toxicity&#xD;
      and patient accrual, in children with very high-risk acute lymphoblastic leukemia.&#xD;
&#xD;
      II. Determine the feasibility and efficacy of following intensified chemotherapy with&#xD;
      allogeneic hematopoietic stem cell transplantation in patients with HLA-matched related&#xD;
      donors.&#xD;
&#xD;
      III. Determine the toxicity of imatinib mesylate in combination with intensified chemotherapy&#xD;
      in Philadelphia chromosome-positive patients.&#xD;
&#xD;
      IV. Determine the event-free survival of patients treated with this regimen. V. Determine&#xD;
      whether minimal residual disease (MDR) after induction therapy and prior to intensification&#xD;
      therapy can predict relapse in these patients.&#xD;
&#xD;
      VI. Determine whether MDR after intensification is prognostically significant. VII. Determine&#xD;
      whether gene expression patterns predict disease recurrence or response to imatinib mesylate.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. This is also a dose-escalation study of imatinib&#xD;
      mesylate in Philadelphia chromosome-positive (Ph+) patients. Patients are stratified&#xD;
      according to Philadelphia chromosome (Ph) status (Ph-positive vs Ph-negative or&#xD;
      indeterminate), hypodiploidy (yes vs no), MLL translocation (11q23) AND slow early response&#xD;
      to prior induction therapy (yes vs no), and failed prior induction therapy (yes vs no).&#xD;
&#xD;
      Cohorts of 8-12 Ph+ patients receive escalating doses of imatinib mesylate, according to the&#xD;
      guidelines for each treatment block of this study, until the maximum tolerated dose (MTD) for&#xD;
      each treatment combination is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity. An additional 35 patients are&#xD;
      treated at the MTD.&#xD;
&#xD;
      CONSOLIDATION BLOCK 1: Patients receive etoposide IV over 1 hour followed by ifosfamide IV&#xD;
      over 1.5 hours on days 1-5. Patients also receive methotrexate intrathecally on day 1 and&#xD;
      filgrastim (G-CSF) subcutaneously (SC) on days 6-15 or until blood counts recover. Patients&#xD;
      with CNS 2/3 at diagnosis also receive intrathecal triple therapy comprising methotrexate,&#xD;
      hydrocortisone, and cytarabine (ITT) on days 8 and 15. Ph+ patients in cohorts 3, 4, and 5&#xD;
      receive oral imatinib mesylate on days 1-21. Within 4 days of starting consolidation therapy,&#xD;
      patients with biopsy-proven testicular leukemia undergo radiotherapy daily for 12 days.&#xD;
&#xD;
      CONSOLIDATION BLOCK 2: Patients receive high-dose methotrexate IV over 24 hours and ITT on&#xD;
      day 1 followed by high-dose cytarabine IV over 3 hours, every 12 hours on days 2 and 3.&#xD;
      Patients also receive leucovorin calcium IV or orally every 6 hours for 3 doses beginning on&#xD;
      day 2, and G-CSF SC on days 4-13 or until blood counts recover. Ph+ patients in cohorts 2, 3,&#xD;
      4, and 5 receive oral imatinib mesylate as in consolidation block 1. Patients undergoing&#xD;
      allogeneic hematopoietic stem cell transplantation (HSCT) proceed to preparative&#xD;
      chemotherapy. All other patients proceed to reinduction block 1.&#xD;
&#xD;
      REINDUCTION BLOCK 1: Patients receive vincristine IV on days 1, 8, and 15; daunorubicin IV on&#xD;
      days 1 and 2; cyclophosphamide IV over 30 minutes, every 12 hours on days 3 and 4;&#xD;
      pegaspargase intramuscularly (IM) on day 4; and ITT on days 1 and 15. Patients also receive&#xD;
      oral dexamethasone twice daily on days 1-7 and 15-21 and G-CSF SC on days 5-14 or until blood&#xD;
      counts recover. Ph+ patients in cohorts 2, 4, and 5 receive imatinib mesylate as in&#xD;
      consolidation block 1.&#xD;
&#xD;
      INTENSIFICATION BLOCK 1: Patients receive high-dose methotrexate IV over 24 hours on days 1&#xD;
      and 15 and ITT on days 1 and 22. Patients also receive leucovorin calcium IV or orally every&#xD;
      6 hours for 3 doses beginning on days 2 and 16. Patients receive etoposide IV over 2 hours&#xD;
      followed by cyclophosphamide IV over 30 minutes on days 22-24; G-CSF SC on days 27-36 or&#xD;
      until blood counts recover; high-dose cytarabine IV over 3 hours, every 12 hours on days 43&#xD;
      and 44; and asparaginase IM on day 44. Ph+ patients in cohorts 1 and 4 receive oral imatinib&#xD;
      mesylate on days 43-63, and patients in cohort 5 receive oral imatinib mesylate on days 1-56.&#xD;
&#xD;
      REINDUCTION BLOCK 2: Patients receive vincristine, daunorubicin, cyclophosphamide,&#xD;
      pegaspargase, dexamethasone, and G-CSF as in reinduction block 1. Patients also receive ITT&#xD;
      on days 1 and 15. Ph+ patients receive imatinib mesylate as in reinduction block 1.&#xD;
&#xD;
      INTENSIFICATION BLOCK 2: Patients receive methotrexate, leucovorin calcium, etoposide,&#xD;
      cyclophosphamide, filgrastim, cytarabine, and asparaginase as in intensification block 1. Ph+&#xD;
      patients receive imatinib mesylate as in intensification block 1.&#xD;
&#xD;
      MAINTENANCE 1: Patients receive high-dose methotrexate IV and leucovorin calcium as in&#xD;
      consolidation block 2. Patients also receive ITT and vincristine IV on days 1 and 29; oral&#xD;
      dexamethasone twice daily on days 1-5 and 29-33; oral methotrexate on days 8, 15, and 22;&#xD;
      oral mercaptopurine on days 8-28; etoposide IV over 2 hours followed by cyclophosphamide IV&#xD;
      over 30 minutes on days 29-33; and G-CSF SC on days 34-43. Ph+ patients in cohorts 1-4&#xD;
      receive oral imatinib mesylate on days 29-49 and patients in cohort 5 receive oral imatinib&#xD;
      mesylate on days 1-56. Treatment repeats every 8 weeks for 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE 2: Patients receive vincristine and dexamethasone as in maintenance 1. Beginning&#xD;
      on day 1, patients undergo cranial radiotherapy once daily, 5 days a week, for approximately&#xD;
      2 weeks. Patients also receive oral methotrexate on days 8, 15, 22, 29, 36, 43, and 50 and&#xD;
      oral mercaptopurine on days 11-56. Ph+ patients in cohorts 1-4 receive oral imatinib mesylate&#xD;
      on days 1-21 and 29-49, and patients in cohort 5 receive oral imatinib mesylate on days 1-56.&#xD;
&#xD;
      MAINTENANCE 3: Patients receive vincristine and dexamethasone as in maintenance 2. Patients&#xD;
      also receive oral methotrexate on days 1, 8, 15, 22, 29, 36, 43, and 50; and oral&#xD;
      mercaptopurine on days 1-56. Ph+ patients receive imatinib mesylate as in maintenance 2.&#xD;
      Treatment repeats every 8 weeks for 7 courses (12 courses total in maintenance 1, 2, and 3)&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients may undergo allogeneic HSCT after consolidation block 2 if there is an available&#xD;
      HLA-DR matched or HLA-A or -B matched or 1 antigen mismatched relative donor.&#xD;
&#xD;
      Patients with CNS leukemia undergo cranial radiotherapy 3 times daily on days -10 to -8. All&#xD;
      patients undergo radiotherapy twice daily on days -7 to -5 and receive etoposide IV on day -4&#xD;
      and cyclophosphamide IV on days -3 and -2. Patients undergo allogeneic bone marrow,&#xD;
      peripheral blood stem cell, or umbilical cord blood transplantation on day 0. Patients&#xD;
      receive cyclosporine IV beginning on day -1 and continuing every 12 hours, switching to oral&#xD;
      administration when possible, until day 60 and tapering thereafter. Patients also receive&#xD;
      methotrexate on days 1, 3, and 6. Beginning 16-24 weeks after transplantation, Ph+ patients&#xD;
      receive oral imatinib mesylate once daily for 24 weeks.&#xD;
&#xD;
      Patients are followed every 4-8 weeks for 1 year, every 3 months for 1 year, every 6 months&#xD;
      for 1 year, and then annually thereafter. Patients undergoing HSCT are followed weekly for&#xD;
      the first year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility, in terms of patient accrual</measure>
    <time_frame>Up to 1.75 years</time_frame>
    <description>As a target goal, we wish to enroll at least 80% of the potential available patients. The accrual duration for this pilot study will be based on accruing adequate numbers to complete the dose escalation study in the Ph+ subset. The planned study accrual duration should be approximately 1.75 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility, in terms of incidence of adverse events graded according to NCI CTC v 2.0</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The use of imatinib as given in combination with other agents in a particular cohort will be considered feasible initially if 5 or more of the first 6 evaluable patients complete the phase(s) without evidence of grade 3 or 4 targeted toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Estimated with 90% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Design Details.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ASNase</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Crasnitin</other_name>
    <other_name>Elspar</other_name>
    <other_name>L-ASP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IT and IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>daunomycin hydrochloride</other_name>
    <other_name>daunorubicin</other_name>
    <other_name>RP-13057</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>IFF</other_name>
    <other_name>IFX</other_name>
    <other_name>IPP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine tablet</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>6-mercaptopurine</other_name>
    <other_name>6-MP</other_name>
    <other_name>Leukerin</other_name>
    <other_name>MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IT, IV, and orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>L-asparaginase with polyethylene glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-ASP</other_name>
    <other_name>PEG-L-asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>cord blood transplantation</other_name>
    <other_name>transplantation, umbilical cord blood</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of acute lymphoblastic leukemia&#xD;
&#xD;
          -  Received prior front-line therapy on a Pediatric Oncology Group (POG),Children's&#xD;
             Cancer Group (CCG), or Central Oncology Group (COG) study&#xD;
&#xD;
          -  Received induction therapy comprising vincristine, asparaginase,&#xD;
             prednisone/dexamethasone, and daunorubicin as in CCG, POG, or COG protocols&#xD;
&#xD;
          -  M1 or M2 bone marrow status after front-line induction therapy and presenting with at&#xD;
             least 1of the following:&#xD;
&#xD;
               -  Philadelphia chromosome positive (Ph+) with t(9;22)(q34;q11) by cytogenetics or&#xD;
                  fluorescence in situ hybridization&#xD;
&#xD;
               -  bcr-abl fusion transcript by reverse transcription polymerase chain reaction&#xD;
&#xD;
               -  Hypodiploid with less than 44 chromosomes and/or DNA index less than0.81&#xD;
&#xD;
               -  MLL translocation (11q23) by cytogenetics and a slow early response (SER) to&#xD;
                  induction therapy, defined as at least 5% blasts at day 15 of induction and/or at&#xD;
                  least .1% minimal residual disease (MRD) after induction therapy&#xD;
&#xD;
          -  Failed to achieve remission after front-line induction therapy&#xD;
&#xD;
               -  M3 bone marrow status (greater than 25% blasts) after induction therapy&#xD;
&#xD;
               -  M2 bone marrow status (5-25% blasts) or at least 1% MRD after induction therapy&#xD;
                  and M2 or M3or at least 1% MRD after consolidation therapy (CCG studies) or&#xD;
                  extended induction therapy (POG or COG studies)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent prophylactic cranial radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirk Schultz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

